Screener
Kalaris Therapeutics KLRS Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Kalaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Kalaris Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219328
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss on extinguishment and on issuance of convertible promissory notes (including $0 and $169 for a related party) | — | (186) |
| Other income, net | 977 | 193 |
| Total other income, net | 977 | 158 |
| Net loss | $(10,856) | $(10,196) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.46) | $(2.52) |
| Weighted-average shares outstanding, basic and diluted | 23,723,618 | 4,053,140 |
| Comprehensive loss: | ||
| Net loss | $(10,856) | $(10,196) |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is Kalaris Therapeutics's net income?
- Kalaris Therapeutics (KLRS) reported net income of -$10.86M in Q1 2026.
- How has Kalaris Therapeutics's net income changed year-over-year?
- Kalaris Therapeutics's net income decreased by 6.5% year-over-year, from -$10.2M to -$10.86M.
- What is the long-term trend for Kalaris Therapeutics's net income?
- Over 3 years (2021 to 2025), Kalaris Therapeutics's net income has grown at a -36.8% compound annual growth rate (CAGR), from -$171.96M to -$43.44M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Kalaris Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude